Mecasermin rinfabate

Mecasermin rinfabate (trade name Iplex) is an injectable medicine used to treat growth failure in children with severe primary insulin-like growth factor-1 (IGF-1) deficiency due to either a genetic deficiency or an acquired deficiency due to underlying diseases such as growth hormone deficiency, small-for-gestational-age, Turner syndrome, or SHOX deficiency. Mecasermin rinfabate is also indicated for the long-term treatment of adults and children with severe primary IGF-1 deficiency to normalize or improve height velocity, body composition, and metabolic parameters.

Mecasermin rinfabate, also known as Iplex (brand name) or rhIGF-1/rhIGFBP-3, is a medication used for a limited set of conditions due to its specific properties. Here's a breakdown of its key aspects:

Function:

  • It combines two components:
    • Recombinant human insulin-like growth factor-1 (rhIGF-1): This component mimics the effects of natural IGF-1, a growth factor crucial for promoting bone and tissue growth.
    • Recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3): This protein helps regulate the activity and lifespan of IGF-1 in the body.

Approved Uses:

  • Severe primary insulin-like growth factor (IGF-1) deficiency: This condition arises when the body doesn't produce enough IGF-1 on its own.
  • Growth hormone insensitivity syndrome (Laron syndrome) with neutralizing antibodies: In such cases, the body cannot effectively utilize growth hormone therapy due to the presence of antibodies that counteract its effects.

Current Status:

  • Limited availability:
    • Patent settlement: Due to legal agreements, Iplex is no longer being marketed for treating short stature related conditions.
    • Research purposes: Iplex is still being investigated for its potential in managing other medical conditions.

Important Notes:

  • Not a first-line treatment: Other medications or therapies might be preferred depending on the specific condition.
  • Close monitoring required: Due to potential side effects, regular medical supervision is crucial throughout treatment.

Potential Side Effects:

  • Similar to Mecasermin, Mecasermin rinfabate can cause side effects such as:
    • Hypoglycemia (low blood sugar)
    • Headache
    • Nausea
    • Injection site reactions

Alternative Treatments:

  • Depending on the underlying cause, stimulating the body's natural IGF-1 production through growth hormone therapy or other medications might be a suitable option.

Seeking Medical Advice:

  • Consultation with a licensed physician, preferably a pediatrician or endocrinologist, is essential for proper diagnosis and treatment plan development.
  • They can assess the individual's specific situation and determine if Mecasermin rinfabate (if available) is the most appropriate course of action.
     
Anatomical Therapeutic Chemical Classification
H - Systemic hormonal preparations, excluding sex hormones and insulins
H01 Pituitary and hypothalamic hormones and analogues
H01A - Anterior pituitary lobe hormones and analogues
H01AC Somatropin and somatropin agonists
External Links